BioCryst Pharmaceuticals | BCRX - 税前利润



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.97B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


税前利润 更改 日
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Chugai Pharma JPY 169.02B 8.83B 2026-06
Daiichi Sankyo JPY -6.52B 113.25B 2026-03
DBV Technologies USD -47.4M 14.24M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novavax USD 17.9M 220.94M 2025-12
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06